Clinical Trial Update: Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a Macrogol 3350-based oral osmotic laxative for preventing colorectal cancer in patients at risk; the study has completed and results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenomatous Polyp
• Colorectal Carcinoma

Drugs mentioned

• Macrogol 3350-based oral osmotic laxative (Polyethylene glycol 3350)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenomatous Polyp, Colorectal Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-01-19